Clinical trial
A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162…
NCT00306189 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00306189 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects |
| Official title | Dose Response Study of AMG 162 (Denosumab) in Subjects With Osteoporosis - A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects - |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | 100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162, Placebo |
| Enrollment | 212 |
| Start date | Jan 1, 2006 |
| Primary completion | Jun 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Mar 23, 2006 |
| Last update posted | Jun 20, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: